{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:51Z","timestamp":1790361711242,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.leukres.2020.106371","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T02:24:33Z","timestamp":1589855073000},"page":"106371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["High serum levels of IL-2R, IL-6, and TNF-\u03b1 are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-4971","authenticated-orcid":false,"given":"Pablo","family":"Mozas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rivas-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Dlouhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Nadeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Balagu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Gonz\u00e1lez-Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycho","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Villamor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00edas","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"P\u00e9rez-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Filella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2020.106371_bib0005","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106371_bib0010","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106371_bib0015","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","article-title":"Transformation of indolent B-cell lymphomas","volume":"29","author":"Montoto","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106371_bib0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2020.106371_bib0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","author":"Federico","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2020.106371_bib0030","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106371_bib0035","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106371_bib0040","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2020.106371_bib0045","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2020.106371_bib0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2020.106371_bib0055","first-page":"244","article-title":"Soluble interleukin 2 receptor \u2013 sIL2R","volume":"97","author":"Yamamoto","year":"2009","journal-title":"Diagn Treat."},{"key":"10.1016\/j.leukres.2020.106371_bib0060","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.leukres.2020.106371_bib0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.leukres.2020.106371_bib0070","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1186\/s12885-019-6057-7","article-title":"Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2020.106371_bib0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-a signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.leukres.2020.106371_bib0080","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12967-018-1611-7","article-title":"Unleashing endogenous TNF-alpha as a cancer immunotherapeutic","volume":"16","author":"Josephs","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.leukres.2020.106371_bib0085","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2141.2005.05393.x","article-title":"Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma","volume":"128","author":"Pedersen","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2020.106371_bib0090","article-title":"Aggressive non-Hodgkin\u2019s lymphoma\u202f: concomitant evaluation of interleukin-2, soluble interleukin-10 and correlation with outcome","volume":"8194","author":"Fabre-Guillevin","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106371_bib0095","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/10428190802108888","article-title":"Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy","volume":"49","author":"Oki","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106371_bib0100","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1349-7006.2009.01167.x","article-title":"Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma","volume":"100","author":"Morito","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.leukres.2020.106371_bib0105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00277-011-1363-4","article-title":"Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens","volume":"91","author":"Goto","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2020.106371_bib0110","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/10428194.2018.1504939","article-title":"Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"60","author":"Umino","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106371_bib0115","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.1973","article-title":"Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18F-FDG PET\/CT in newly diagnosed patients with diffuse large B-cell lymphoma","volume":"8","author":"Senjo","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2020.106371_bib0120","first-page":"1","article-title":"Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma","volume":"0","author":"Umino","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106371_bib0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2017.05.014","article-title":"High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma","volume":"59","author":"Dlouhy","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2020.106371_bib0130","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1200\/JCO.2005.26.856","article-title":"Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors","volume":"23","author":"de Jong","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106371_bib0135","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2017-11-764365","article-title":"Critical influences on the pathogenesis of follicular lymphoma","volume":"131","author":"K\u00fcppers","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106371_bib0140","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clml.2013.03.014","article-title":"Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma","volume":"13","author":"Yoshizato","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2020.106371_bib0145","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3109\/10428194.2013.850167","article-title":"Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era","volume":"55","author":"Proch\u00e1zka","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106371_bib0150","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood-2014-06-583369","article-title":"Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma","volume":"125","author":"Mir","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106371_bib0155","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1038\/bcj.2017.96","article-title":"High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy","volume":"7","author":"Kusano","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2020.106371_bib0160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10245332.2017.1312204","article-title":"Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP","volume":"22","author":"Umino","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2020.106371_bib0165","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/10428194.2016.1190975","article-title":"Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma","volume":"58","author":"Umino","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106371_bib0170","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106371_bib0175","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of $K$-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann. Stat."},{"key":"10.1016\/j.leukres.2020.106371_bib0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.17219\/acem\/62120","article-title":"IL-6, IL-8 and TNF-\u03b1 levels correlate with disease stage in breast cancer patients","volume":"26","author":"Ma","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.leukres.2020.106371_bib0185","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601814","article-title":"Serum levels of IL-6 and TNF-\u03b1 correlate with clinicopathological features and patient survival in patients with prostate cancer","volume":"90","author":"Michalaki","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2020.106371_bib0190","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2010.140145","article-title":"Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage","volume":"70","author":"Grivennikov","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.leukres.2020.106371_bib0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2011.02.007","article-title":"The microenvironment in follicular lymphoma","volume":"24","author":"De Jong","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.leukres.2020.106371_bib0200","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.21873\/anticanres.13706","article-title":"Soluble Interleukin-2 receptor level at diagnosis predicts prognosis of patients with follicular lymphoma irrespective of initial management strategy","volume":"39","author":"Yamamoto","year":"2019","journal-title":"Anticancer Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262030076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262030076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:14Z","timestamp":1758934814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262030076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":40,"alternative-id":["S014521262030076X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106371","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High serum levels of IL-2R, IL-6, and TNF-\u03b1 are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106371"}}